3 Monster Stocks in the Making to Buy Right Now

From an analytical perspective, Where can you find the next monster stocks

Check out the bio space

It's not easy, but investors can sometimes find highly mising bio stocks that are only in their early innings

Three Motley Fool contributors think they've identified monster stocks in the making

Image source: Getty Images

The gene editing market is still fairly small, but it has a lot of room to grow

As a leading company in the space, CRISPR Therapeutics is well positioned to benefit from future growth in this area of healthcare (which is quite significant)

Conversely, The company, and its key development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), already have an apved gene therapy treatment in Casgevy, which regulators have apved for both sickle cell disease and transfusion-dependent beta-thalassemia, considering recent developments

Casgevy is still in its early growth stages

CRISPR is also working on treatments for type 1 diabetes and cardiovascular disease

However, While CRISPR remains unfitable today, its future does look bright, in today's financial world

It's a long road ahead for CRISPR Therapeutics, but with an encouraging pipeline and a lot of growth potential, this could be a monster healthcare stock in the making, in today's financial world

On the other hand, CRISPR can make for an excellent investment, but it's also one you'll need to be patient with

Still plenty of upside left for this stock sper Junior Bakiny (Summit Therapeutics): Few bio companies have performed better than Summit Therapeutics over the past three years

Here's the good news for those who are still considering the stock: There could be a massive upside left for Summit Therapeutics

Though the bio generates no revenue and is unfitable, it has one of the more mising pipeline ducts in the industry

On the other hand, Summit Therapeutics' leading candidate is a cancer medicine called ivonescimab, which it licensed out from Akeso Biopharma (OTC: AKES, in today's financial world

F), a China-based drug developer

Additionally, The medicine has been extensively tested in China, where it has already received apval in certain indications

One of ivonescimab's most mising is non-small cell lung cancer (NSCLC)

In a phase 3 study in China, it went head-to-head against the market leader and the world's best-selling drug: Merck's (NYSE: MRK) Keytruda (something worth watching)

Ivonescimab emerged victorious, leading to a greater decrease in the risk of recurrence or death among NSCLC patients with a PD-L1 tein overexpression

Summit Therapeutics is conducting clinical studies to support apval in the U

In contrast, Furthermore, the bio is ly to seek a series of apvals and label expansions over the years, based on the number of clinical trials and indications Akeso is targeting in China, in light of current trends

Ivonescimab should easily become a blockbuster and generate strong sales for years, in this volatile climate

Nevertheless, That's why it's not too late to invest in Summit Therapeutics

On the other hand, If ivonescimab achieves its full potential, Summit could der market-beating returns in the next five to 10 years and establish itself as a minent player in the bio industry

The company recently advanced a subcutaneous formulation of this candidate into late-stage clinical testing after announcing highly encouraging results from a phase 2 study last year, in today's financial world

Obesity isn't the only big market that the company is targeting, though

In 2023, Viking reported positive results from a phase 2 study of VK2809 in treating metabolic-associated steatohepatitis (MASH), a chronic r disease also known as nonalcoholic steatohepatitis (NASH)

In contrast, However, I think the company's chances look pretty good, in light of current trends

I also wouldn't be surprised if a larger drugmaker swoops in to acquire Viking (an important development), in this volatile climate.